mobocertinib (Exkivity)

Indications

• 2nd-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations

* amivantamab (Rybrevant) is the only other FDA-approved therapy for NSCLC with EGFR exon 20 insertion mutations

Adverse effects

• diarrhea (91%), rash (45%), paronychia (38%), decreased appetite (35%), nausea (34%), dry skin (31%), vomiting (30%), increased serum creatinine (25%), stomatitis (24%), pruritus (21%)

* boxed warning: QTc prolongation & Torsades de Pointes

* warnings & precautions for interstitial lung disease/pneumonitis, cardiac toxicity, & diarrhea

• drug adverse effects of tyrosine kinase inhibitor(s)

More general terms

• small inhibitory antineoplastic agent (ib drug)
• tyrosine kinase inhibitor